Axovant Sciences Ltd. (AXON) Comes Under Scrutiny Amid IPO Surge
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/25/2026
- S&P 500 ends marginally lower as investors focus on US-Iran war
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oil gains on little sign of progress in US-Iran talks
- S&P 500 history shows strong gains across Fed hiking cycles: BCA
- JPMorgan upgrades CoreWeave on stronger compute pricing
- Bloom Energy falls as Oracle invokes force majeure on AI project
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Akamai signs $11.6B deal with Anthropic, up to $20B potential
- Oracle Sends Force Majeure Notice Over New Mexico Data Center - Bloomberg
- US and Iran discuss phased deal to reopen Hormuz and end US blockade, sources say
Axovant Sciences Ltd. Announces Pricing of Initial Public Offering
June 10, 2015 10:43 PM EDTHAMILTON, Bermuda, June 10, 2015 /PRNewswire/ --Â Axovant Sciences Ltd. (NYSE: AXON), a clinical-stage biopharmaceutical company, today announced the pricing of its initial public offering of 21,000,000 common shares at a price of $15.00 per share. The common shares of Axovant Sciences Ltd. have been approved for listing on the New York Stock Exchange and are expected to begin trading under the ticker symbol "AXON" on June 11, 2015. All of the common shares are being offered by Axovant Sciences Ltd. In addition, Axovant Sciences Ltd. has granted the underwriters a 30-day option to purchase up to... More
